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Genetic variation 
Objectives 
• Identify genetic factors that influence the 
risk of prevalent chronic diseases in the 
Portuguese population; 
• Characterize the contribution of different 
genetic factors to chronic disease 
susceptibility. 
 
4 
1) Population sample  
Materials and methods 
•221 participants (95 men and 126 women). 
  
•Pilot study of INSEF – “Inquérito Nacional de Saúde com 
exame Fisico” - the National Component of the European 
Health Examination Survey project. 
 
• São Brás de Alportel Health Center 
 
• Random sampling of participants by SNS identification 
number 
 
•In accordance with EHES procedures to achieve maximum 
participating rates and quality of the data and samples 
 
Materials and methods 
2) Phenotype characterization:  
     Detailed Questionnaire, (sociodemographics 
and occupation, medical history and general 
health, family history of illness focusing on chronic 
disorders, psychological status, and lifestyle 
exposures (including smoking, alcohol, physical 
activity and diet)  
 Physical exam (weight, height, waist and hip 
circumpherence, blood pressure) 
     Blood sample (Glucose, HDL, LDL, 
Triglycerides, GGT, ALT, AST, Creatinine, C 
Reactive protein) CBC + Serum, Plasma and 
DNA for Biobanking 
3) Candidate gene analysis 
  
 Blood sample            DNA Extraction 
SNP analysis 
3) Candidate gene analysis 
3.1 Candidate Genes SNPs selection (described in literature) 
 
82 diferent Genes associated to: 
• Cancer 
• Drug resistance/metabolism 
• Cardiovascular diseases 
• Diabetes 
• Obesity 
• Psychiatric disorders 
• Drug addiction 
RFLPs 
Potential Public 
Health Impact 
Sequenom-Massarrays 
3.2 Genotyping:  
Continuous 
Variables 
HES 
Database 
Genotypes 
Associations 
Lifestyle 
behaviours  
Genotype Database $ 
To identify genetic risk factors involved in chronic 
disease susceptibility, using continuous variables.  
Phenotype Database $ 
Materials and methods 
Population characterization 
  Total Men Women P-value* 
Number of participants 206 87 (42,2%) 119 (57,8%)   
Age (years±SD) 56,31 ± 16,37 55,80 ± 16,45 56,67 ± 16,37 0,754 
BMI(Kg/m
2
) 27,88 ± 4,69 27,44± 4,20 28,20± 5,01 0,336 
MetS 
1
 95 (46,1%) 40 (46,0%) 55 (46,2%) 0,124 
MetS risk factors (mean±SD)         
Waist circumference (cm) 95,50 ± 12,56 97,62 ± 1,72 93,94 ± 12,97 3,8x10
-2
 
DBP (mmHg) 80,67 ± 9,96 80,89 ± 10,02 80,52 ± 9,95 0,793 
SBP (mmHg) 131,72 ± 20,02 133,00 ± 16,38 130,79 ± 22,33 0,245 
HDL (mg/dL) 53,51 ± 13,33 49,61 ± 12,85 56,35 ± 12,99 2,5x10
-4
 
TG (mg/dL) 107,71 ± 60,29 115,26 ± 74,73 102,19 ± 46,61 0,717 
Glucose (mg/dL) 103,29 ± 33,91 109,79 ± 47,10 98,54 ± 1,66 2,6x10
-4
 
MetS related diseases
2
         
Hypertension  54 (26,2%) 20 (23,0%) 34 (28,6%) 0,054 
Type 2 Diabetes  15 (7,3%) 8 (9,2%) 7 (5,9%) 0,796 
Hypercholesterelomia  26 (12,6%) 7(8,0%) 19 (16,0%) 0,019 
TOTAL 95 (46,1%) 35(40,2%) 60 (50,4%) 
Medication 
Hypertension  52 (25,2%) 19 (21,8%) 33 (27,7%) 0,052 
Type 2 Diabetes  13 (6,3%) 6 (6,9%) 7 (5,9%) 0,782 
Hypercholesterelomia  24 (11,7%) 6 (6,9%) 18 (15,1%) 0,014 
TOTAL 89 (43,2%) 31 (35,6%) 58 (48,7%) 
Smoking status 
Current smokers  37 (18,0%) 19 (21,8%) 18 (15,2%) 0,869 
Former smokers  42 (20,5%) 32 (36,8%) 10 (8,5%) 0,001 
Never smokers  126 (61,5%) 36 (41,4%) 90 (76,3) 1,5x10
-6
 
Regular Physical activity  80 (39,6%) 35 (40,2%) 45 (37,8%) 0,264 
Table1. Characteristics of men and women participants (Data are presented as mean±SD for 
continuous variables and n (%) for proportions). 
Genotype database 
ID SNP1 SNP2 … SNP105 
1 AA TG … CC 
2 AT GG CA 
3 TT TT … AA 
… … … … … 
… … … … … 
… … … … … 
208 TT GG … CC 
105 SNPs Genotyped SNPs  
 
INSEF sample:208 
 
≈61000 Genotypes 
Selected 
from 
bibliography 
Sequenom 
Genotyped 
RFLPs 
Genotyped  
Failed  Successfull 
Number of SNPs 114 73 41 9 105 
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1. Waist circumference   Men≥94 cm 
                                    Women≥80 cm 
2. Blood pressure ≥130/85mmHg or Medication  
     
3. TG ≥150mg/dL or Medication 
5. HDL  Men≤40mg/dL      or Medication 
            Women≤50mg/dL 
4. Glucose ≥100mg/dL or Medication   
Alberti et al, 2009 
Metabolic Syndrome (MetS) 
≥3 risk factors:  MetS Diagnosis 
Figure 1. Prevalence of MetS and its risk factors. Participants medicated for 
hypertension, hypercholesterelomia and diabetes were also accounted. Error 
bars represent the 95% confidence intervals. Abbreviations: MetS, metabolic 
syndrome; DBP, diastolic blood pressure; SBP, systolic blood pressure; HDL, high 
density lipoprotein cholesterol; TG, triglycerides 
• Simple clinical tool for predicting diabetes and CVD and the 
conceptual basis for understanding at least part of the 
pathopgysiological link between metabolic risk, future 
diabetes and CVD; 
• Provides a framework for reserach exploring a possible 
unifying pathophysiological basis for the observed cluster of 
risk factors; 
• It can guide relative risk prediction and clinical management 
decisions; 
• It provides na easily comprehensive public health message 
and reminds health professionals of the need to assess 
related risk factors when one risk factor is detected. 
Why Metabolic Syndrome (MetS) approach? 
Dichotomized MetS definition  
vs  
Continuous MetS Score 
Dichotomized definition of MetS enabling a yes or no 
diagnosis remains useful to clinical practice 
 
BUT 
 
in genetic epidemiological approaches , it reduces the 
statistical power of the MetS association studies and a 
continuous MetS score will be a more appropriate alternative 
 
Principal Components Analysis 
(Wijindaele et al. 2006) 
6 Risk factors 
Wais circumference 
Diastolic Bloood pressure 
Systolic Blood pressure 
Glucose 
TG 
HDL 
MetS Score 
Normalization 
log10[log10(Systolic BP)]  
1/[log10(Glucose)]
10  
[ln(HDL)]2  
log10[log10(TG)]  
Diferences between Sexes 
(T-test or Mann-Whitney test ) 
Normality Test (Shapiro-Wilk Test) 
Higher MetS score 
 =  
Less favorable MetS profile 
MetS Score 
15 
Continuous MetS score calculation by PCA analysis 
Men 
 
• PC1 and PC2 explain 35,9% and 
27,4% of MetS score variance 
 
• measured correlations  
PC1 [PC2]:  
Waist circumference 0,650[0,255] 
Systolic blood pressure 0,826[0,057] 
Diastolic blood pressure 0,771[0,320] 
Glucose -0,598[0,147]  
HDL 0,079[-0,885]  
Triglycerides 0,305[0,818]. 
 
Women 
 
• PC1 and PC2 explain 36,7% and 
25,1% of MetS score variance 
 
• measured correlations  
PC1[PC2]: 
waist circumference 0,491[0,381] 
Systolic blood pressure 0,891[0,019]  
diastolic blood pressure 0,812[0,018]   
glucose -0,661 [-0,251] 
HDL 0,047 [-0,838] 
triglycerides 0,266 [0,770] 
The result MS score was 0,00±1,41 in both genders  
16 
5. Results 
Figure 2- Variation of the MSscore descriptive statistics according to the 
number of risk factors. The 5 risk factors considered are those presented 
in the consensus MetS definition 
MetS score increases progressively with increasing numbers of risk 
factors (ANOVA test p<0,001).  
17 
Individual association with MetSscore (T-test) 
Genotype Database 
Candidate gene analysis 
13 SNPs Type 2 
Diabetes 
7 SNPs Cardiovascular 
Diseases 
9 SNPs 
Obesity 
3 SNPs 
Dyslipidemias 
5 Drug/Lipid 
metabolism 
Multiple testing correction 
(Bonferroni Test) 
18 
5. Results 
Table 2-List of SNPs selected in the present study.  
(Abreviations: MAF,Minor allele frequency 
Gene NCBI ID Alteration Related traits  European MAF1 Obtained MAF 
CDKAL1 rs7754840 C→G Type 2 Diabetes 0,336   0,286 
CDKN2A/B rs10811661 C→T 0,199   0,201 
HHEX rs1111875 A→G 0,416   0,371 
IGF2BP2 rs4402960 G→T 0,280   0,272 
IL6 rs1800795 C→G 0,465   0,337 
KCNJ11 rs5219 C→T -  0,333 
KCNQ1 rs2237892 C→T 0,075   0,051 
MTNR1B rs10830963 C→G 0,300   0,223 
PPARG rs1801282 C→G 0,076   0,093 
SLC30A8 rs13266634 C→T 0,239   0,286 
TCF7L2 rs7903146 C→T 0,279   0,302 
ADCY5 rs11708067 A→G 0,226  0,199 
KCNQ1 rs231362 C→T 0,482   0,234 
ACE rs4646994 Ins/Del Cardiovascular diseases -  0,420 
NOS1AP rs12143842 C→T 0,188   0,265 
ADRB1 rs1801252 A→G -  0,108 
ADRB2 rs1042714 C→G 0,467   0,407 
ADRB2 rs1042713  A→G 0,358   0,362 
NOS3 rs1799983 G→T 0,342   0,417 
NOS3 rs2070744 C→T -  0,451 
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5. Results 
Table 2-List of SNPs selected in the present study 
(continuation). 
Gene NCBI ID Alteration Related traits  European MAF1 Obtained MAF 
GNPDA2 rs10938397 A→G Obesity 0,446   0,481 
MTCH2 rs10838738 A→G 0,363   0,282 
NPC1 rs1805081 A→G 0,467   0,288 
PTER rs10508503 C→T 0,092   0,075 
SH2B1 rs7498665 A→G 0,382   0,303 
FTO rs9939609 A→T 0,449  0,361 
ADRB3 rs4994 C→T 0,088   0,090 
GABRA2 rs279871 A→G -  0,434 
TMEM18 rs6548238 C→T 0,150   0,127 
APOE rs7412 C→T Dyslipidemia -  0,027 
LDLR rs2228671 C→T 0,106   0,124 
NPY rs16147 A→G 0,491   0,450 
CYP2C8 rs10509681 C→T Drug/Lipid metabolism 0,137  0,129 
CYP2C9 rs1799853 C→T 0,104   0,138 
CYP2D6 rs16947 A→G -  0,393 
CYP2C19 rs4244285 G→A 0,155  0,129 
TPMT rs1142345 A→G 0,027  0,032 
20 
5. Results 
Gene SNP ID Genotype n MetSscore P-value* Corrected P-value* 
CYP2C19 rs4244285 GG 156 0,19±1,37 0,00044 0,016 
AA+GA 50 -0,6±1,36 
GABRA2 rs279871 AA 63 0,37±1,35 0,013 0,487 
GG+GA 143 -0,16±1,41 
NPY rs16147 AA 58 0,38±1,63 0,017 0,612 
GG+GA 148 -0,15±1,29 
TPMT rs1142345 AA 192 -0,07±1,38 0,0098 0,360 
GA 13 0,97±1,63 
Table 3. Polymorphism significantly associated with MetS score. 
(MetS score are presented as mean±SD). 
*P-value were obtanied by T-test and Corrected P-value were obtained by 
Bonferroni Correction. 
• Multiple linear regression Models 
1 Age 
2 Age+CYP2C19 
3 Age+CYP2C19+GABRA2 
4 Age+CYP2C19+GABRA2+NPY 
5 Age+CYP2C19+GABRA2+NPY+TPMT 
 
ANOVA test p<0,001 for all the models 
• Age is as an important risk factor. 
• Age + 4 genetic variants explain 23% of the MetS score variation. 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 ,355 ,126 ,122 1,32334 
2 ,418 ,175 ,167 1,28904 
3 ,455 ,207 ,195 1,26702 
4 ,472 ,223 ,208 1,25706 
5 ,500 ,250 ,231 1,23807 
Additive genetic effects 
No association was found with environmental factors – lack of statistical power 
Underlying phenotypes 
GABRA2 rs279871 P=0.026 
NPC1 rs1805081 P=0.039 
NPY rs16147 P=0.024 
GABRA2 rs279871 P=0.014 
ADRB2 rs1042713 P=0.027 
ADRB3 rs4994 P=0.040 
CYP2C19 rs4244285 P=0.011 
CYP2C19 rs4244285 P=0.014 
ADRB2 rs1042713 P=0.027 
ADRB3 rs4994 P=0.040 
CYP2C8 rs10509681 P=0.017 
MTNR1B rs10830963 P=0.048 
ADRB3 rs4994 P=0.040 
NPY rs16147 P=0.005 
 
Multiple regression models only explain 5-10% of the phenotype variance 
Additive genetic effects 
ADCY rs11708067 P=0.0056 
CYP2C19 rs4244285 P=0.0046 
GABRA rs279871 P=0.0455 
TMEM18 rs6548238 P=0.0078 
 
CYP2C19 rs4244285 P=0.0366 
TPMT  P=0.0202 
 
CYP2C19 rs4244285 P=0.0280 
CYP2C8 rs10509681 P=0.0400 
CYP2C9 rs1799853 P=0.0130 
GABRA rs279871 P=0.0200 
NPC1 rs1805081 P=0.0240 
NPY rs16147 P=0.0350 
TPMT  P=0.0240 
Multiple regression models only explain 5-10% of the phenotype variance 
Conclusions 
• The quatitative MetS score has more power to detect association than the 
tradicional MetS dichotomous definition; 
• We have found a significant association between genetic variants in the CYP2C19, 
GABRA2, NPY and TPMT  genes and the MetS quantitave score; 
• Age + 4 genetic variants explain 23% of the MetS score variation; 
• These genes are possibly involved in a pathophysiological mechanism responsible 
for the clustering of metabolic risk factors; 
• No association is found between the phenotype using the traditional MetS 
definition and the analysed genetic variants; 
• No association was found with environmental factors, likely due to lack of 
statistical power. 
Genetic susceptibility to Influenza infection 
• Infectious disease mortality risk has a heritable component. Children of 
parents who died of an infectious disease are 6x more likely to die from an 
infectious cause compared with the general population;  
• An investigation of the influenza death records over the past 100 years in 
the population of Utah provided evidence for an increased risk in close and 
distant related relatives 
• In some recent familial clusters of H5N1 infection, fatal cases curiously 
clustered among relatives .  
• More recently, a pilot study of host genetic variants associated with 
influenza-related deaths among children and young adults has revealed that 
individuals who died of influenza had low producing Mannose-binding lectin 
2 (MBL2) genotypes conferring increased risk for Methicillin-resistant 
Staphylococcus aureus (MRSA) co-infection .  
Olsen et al., 2005 
Ferdinands et al., 2011 
Horby et al., 2010 
Objectives 
• To identify and characterize host and virus 
genetic factors that influence susceptibility, 
severity and outcome of 2009 pandemic 
influenza A (H1N1) and to identify host-
virus additive and non-additive interactions 
that would lead to increased susceptibility, 
severity or outcome of this infection.  
Materials and methods 
1. Perform a case-control genetic association study using the nasal swab 
samples that have been collected and sent to the INSARJ for diagnostic 
purposes during the A (H1N1) pandemic on the context of the National 
Influenza Surveillance Program (NISP) – targeted sequencing of 
candidate genes; 
2. Dissect viral genetic diversity by sequencing genomic segments of 150 
virus present in randomly selected samples in each of the previously 
established groups of influenza cases (mild and severe); 
3. Analyze how host and viral genetic variation interact to influence disease 
susceptibility and/or severity. 
Study design 
2009 Pandemics 
Severe cases 
(Hospitalized) 
Mild cases 
(Non hospitalized) 
ILI H1N1 influenza virus 
positive 
96 (56M+40F) 212(115M+97F) 
ILI - H1N1 influenza 
virus negative 
198 (110M+88F) 403 (217M+186F) 
IFITM3 and influenza infection 
Everitt et al., 2012 
Everitt et al., 2012 
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